Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Cranston

Showing results (231-240 of 259) with videos related to

Pageof 26
Sort By:
American Journal of Epidemiology|December 7, 2014
Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adultsDaniel C Beachler, Elizabeth A Sugar, Joseph B Margolick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 17, 2018
A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298Timothy J Wilkin, Huichao Chen, Michelle S Cespedes, et al.
The Journal of Infectious Diseases|July 3, 2023
Impact of Obefazimod on Viral Persistence, Inflammation, and Immune Activation in People With Human Immunodeficiency Virus on Suppressive Antiretroviral TherapySilvia Bernal, Maria C Puertas, Sara Morón-López, et al.
The Journal of Infectious Diseases|May 9, 2015
High Oral Human Papillomavirus Type 16 Load Predicts Long-term Persistence in Individuals With or at Risk for HIV InfectionDaniel C Beachler, Yingshi Guo, Wiehong Xiao, et al.
AIDS Research and Human Retroviruses|June 1, 2019
A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIVRoss D Cranston, Charlene S Dezzutti, Aaron Siegel, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2019
Brief Report: Routine Use of Oral PrEP in a Phase 2 Rectal Microbicide Study of Tenofovir Reduced-Glycerin 1% Gel (MTN-017)Albert Y Liu, Aliza Norwood, Holly Gundacker, et al.
Plos One|March 21, 2015
Association between free testosterone levels and anal human papillomavirus types 16/18 infections in a cohort of men who have sex with menHilary K Hsu, Todd T Brown, Xiuhong Li, et al.
Plos One|July 1, 2016
Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender WomenIan McGowan, Ross D Cranston, Kenneth H Mayer, et al.
AIDS Research and Human Retroviruses|September 20, 2021
An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil FumarateIan M McGowan, Ratiya Pamela Kunjara Na Ayudhya, Rhonda M Brand, et al.
Cytokine|April 12, 2016
Association of serum cytokines with oral HPV clearanceJennifer O Lam, Jay H Bream, Elizabeth A Sugar, et al.
Pageof 26

Showing results (231-240 of 259) with videos related to

Sort By:
Pageof 26
American Journal of Epidemiology|December 7, 2014
Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adultsDaniel C Beachler, Elizabeth A Sugar, Joseph B Margolick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 17, 2018
A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298Timothy J Wilkin, Huichao Chen, Michelle S Cespedes, et al.
The Journal of Infectious Diseases|July 3, 2023
Impact of Obefazimod on Viral Persistence, Inflammation, and Immune Activation in People With Human Immunodeficiency Virus on Suppressive Antiretroviral TherapySilvia Bernal, Maria C Puertas, Sara Morón-López, et al.
The Journal of Infectious Diseases|May 9, 2015
High Oral Human Papillomavirus Type 16 Load Predicts Long-term Persistence in Individuals With or at Risk for HIV InfectionDaniel C Beachler, Yingshi Guo, Wiehong Xiao, et al.
AIDS Research and Human Retroviruses|June 1, 2019
A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIVRoss D Cranston, Charlene S Dezzutti, Aaron Siegel, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2019
Brief Report: Routine Use of Oral PrEP in a Phase 2 Rectal Microbicide Study of Tenofovir Reduced-Glycerin 1% Gel (MTN-017)Albert Y Liu, Aliza Norwood, Holly Gundacker, et al.
Plos One|March 21, 2015
Association between free testosterone levels and anal human papillomavirus types 16/18 infections in a cohort of men who have sex with menHilary K Hsu, Todd T Brown, Xiuhong Li, et al.
Plos One|July 1, 2016
Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender WomenIan McGowan, Ross D Cranston, Kenneth H Mayer, et al.
AIDS Research and Human Retroviruses|September 20, 2021
An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil FumarateIan M McGowan, Ratiya Pamela Kunjara Na Ayudhya, Rhonda M Brand, et al.
Cytokine|April 12, 2016
Association of serum cytokines with oral HPV clearanceJennifer O Lam, Jay H Bream, Elizabeth A Sugar, et al.
Pageof 26